2025 Q2 -tulosraportti
148 päivää sitten37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
1 000
Myynti
Määrä
25 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 10.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 25.4.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·6 t sittenCan someone tell me if it's actually true that one can only use the subscription rights with an IKZ- or IPA-account? According to Nordnet's website, it doesn't even work with an AF-account. Nor can I buy more subscription rights with an ASK-account.
·10 t sittenStrange almost no one seems to care about the subscription rights. The share is worth 1.15. But if you buy the subscription right for 13 øre you get the share for 1.13 AND a warrant that potentially can be worth a fair bit. If the share stands at 1.50 in May you get the right to buy the share for 1.20. Thus an implicit value of 30 øre. At a share price of 2 in May the warrant is worth 40 øre.
·9 t sittenYou are absolutely right, I myself increased the number of rights today, though only by 20000 units. The brilliant thing here is that massive updates are expected before warrants must be exercised- it will take a lot for this, as a pure base case, not to be somewhere between 1,40-1,60,- by May. I hadn't expected the rights to be so cheap... Had I known that, I would probably have traded in significantly more and set aside in advance for the purchase and exercise of rights. I believe it's a lack of competence that prevents the rights from being priced higher- regardless, they can no longer be traded after market close tomorrow... and then the 20 percent train has, in that respect, left the platform
14 t sitten14 t sittenNo one else here dare to say it. But your next oil has been found. Welcome to biotekeventyret. There is some world-class knowledge and innovations on biotek at Norway. I dont mean just Circio others too.
·9 t sittenI believe they just crushed Bergen bio in the latest call, which is one of the companies larger investors have gotten burned on before. Circio is doing groundbreaking research unlike them and several others. Thor medical can certainly be compared, which was formed from Nanovektor, the cancer venture that went belly up. The difference is that Thor switched to "natural resources" which the Norwegian state and politicians embrace with convulsions, and investors and Norwegian partners chase after. Circio operates within the concepts "gene" "rna", and it's the bomb, as the kids say. Now Circio is really flexing its muscles, because they have been clever enough to focus away from Norway. We who have sat and had steadfast faith, rejoice over the gravitas and capacity of the team at Circio. I'm quite sure this will go well now😊
·16 t sittenAs posted earlier this week 1.35 technical https://x.com/trondyman/status/2013594929046393259?s=46- ·17 t sittenThe analysis that came today is important because it reaches brokerage firms, funds, and professional investors. These have probably not understood the circVec technology and its potential as there have been no serious analyses previously. Such an approach is not uncommon, and in any case, the analyst vouches for the content. It provides a good introduction to the case. It is not at all bullish, even though I myself think the price targets are low, so they have been cautious, and that is probably wise.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
148 päivää sitten37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenCan someone tell me if it's actually true that one can only use the subscription rights with an IKZ- or IPA-account? According to Nordnet's website, it doesn't even work with an AF-account. Nor can I buy more subscription rights with an ASK-account.
- ·10 t sittenStrange almost no one seems to care about the subscription rights. The share is worth 1.15. But if you buy the subscription right for 13 øre you get the share for 1.13 AND a warrant that potentially can be worth a fair bit. If the share stands at 1.50 in May you get the right to buy the share for 1.20. Thus an implicit value of 30 øre. At a share price of 2 in May the warrant is worth 40 øre.·9 t sittenYou are absolutely right, I myself increased the number of rights today, though only by 20000 units. The brilliant thing here is that massive updates are expected before warrants must be exercised- it will take a lot for this, as a pure base case, not to be somewhere between 1,40-1,60,- by May. I hadn't expected the rights to be so cheap... Had I known that, I would probably have traded in significantly more and set aside in advance for the purchase and exercise of rights. I believe it's a lack of competence that prevents the rights from being priced higher- regardless, they can no longer be traded after market close tomorrow... and then the 20 percent train has, in that respect, left the platform
- 14 t sitten14 t sittenNo one else here dare to say it. But your next oil has been found. Welcome to biotekeventyret. There is some world-class knowledge and innovations on biotek at Norway. I dont mean just Circio others too.·9 t sittenI believe they just crushed Bergen bio in the latest call, which is one of the companies larger investors have gotten burned on before. Circio is doing groundbreaking research unlike them and several others. Thor medical can certainly be compared, which was formed from Nanovektor, the cancer venture that went belly up. The difference is that Thor switched to "natural resources" which the Norwegian state and politicians embrace with convulsions, and investors and Norwegian partners chase after. Circio operates within the concepts "gene" "rna", and it's the bomb, as the kids say. Now Circio is really flexing its muscles, because they have been clever enough to focus away from Norway. We who have sat and had steadfast faith, rejoice over the gravitas and capacity of the team at Circio. I'm quite sure this will go well now😊
- ·16 t sittenAs posted earlier this week 1.35 technical https://x.com/trondyman/status/2013594929046393259?s=46
- ·17 t sittenThe analysis that came today is important because it reaches brokerage firms, funds, and professional investors. These have probably not understood the circVec technology and its potential as there have been no serious analyses previously. Such an approach is not uncommon, and in any case, the analyst vouches for the content. It provides a good introduction to the case. It is not at all bullish, even though I myself think the price targets are low, so they have been cautious, and that is probably wise.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 000
Myynti
Määrä
25 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 10.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 25.4.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
2025 Q2 -tulosraportti
148 päivää sitten37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 10.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2024 Q4 -tulosraportti | 10.4.2025 | |
| 2024 Q2 -tulosraportti | 29.8.2024 | |
| 2023 Q4 -tulosraportti | 25.4.2024 | |
| 2023 Q3 -tulosraportti | 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenCan someone tell me if it's actually true that one can only use the subscription rights with an IKZ- or IPA-account? According to Nordnet's website, it doesn't even work with an AF-account. Nor can I buy more subscription rights with an ASK-account.
- ·10 t sittenStrange almost no one seems to care about the subscription rights. The share is worth 1.15. But if you buy the subscription right for 13 øre you get the share for 1.13 AND a warrant that potentially can be worth a fair bit. If the share stands at 1.50 in May you get the right to buy the share for 1.20. Thus an implicit value of 30 øre. At a share price of 2 in May the warrant is worth 40 øre.·9 t sittenYou are absolutely right, I myself increased the number of rights today, though only by 20000 units. The brilliant thing here is that massive updates are expected before warrants must be exercised- it will take a lot for this, as a pure base case, not to be somewhere between 1,40-1,60,- by May. I hadn't expected the rights to be so cheap... Had I known that, I would probably have traded in significantly more and set aside in advance for the purchase and exercise of rights. I believe it's a lack of competence that prevents the rights from being priced higher- regardless, they can no longer be traded after market close tomorrow... and then the 20 percent train has, in that respect, left the platform
- 14 t sitten14 t sittenNo one else here dare to say it. But your next oil has been found. Welcome to biotekeventyret. There is some world-class knowledge and innovations on biotek at Norway. I dont mean just Circio others too.·9 t sittenI believe they just crushed Bergen bio in the latest call, which is one of the companies larger investors have gotten burned on before. Circio is doing groundbreaking research unlike them and several others. Thor medical can certainly be compared, which was formed from Nanovektor, the cancer venture that went belly up. The difference is that Thor switched to "natural resources" which the Norwegian state and politicians embrace with convulsions, and investors and Norwegian partners chase after. Circio operates within the concepts "gene" "rna", and it's the bomb, as the kids say. Now Circio is really flexing its muscles, because they have been clever enough to focus away from Norway. We who have sat and had steadfast faith, rejoice over the gravitas and capacity of the team at Circio. I'm quite sure this will go well now😊
- ·16 t sittenAs posted earlier this week 1.35 technical https://x.com/trondyman/status/2013594929046393259?s=46
- ·17 t sittenThe analysis that came today is important because it reaches brokerage firms, funds, and professional investors. These have probably not understood the circVec technology and its potential as there have been no serious analyses previously. Such an approach is not uncommon, and in any case, the analyst vouches for the content. It provides a good introduction to the case. It is not at all bullish, even though I myself think the price targets are low, so they have been cautious, and that is probably wise.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 000
Myynti
Määrä
25 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt